A pilot study in 22 women with active rheumatoid arthritis has indicated that treatment with the anti-IL-6 antibody tocilizumab might provide beneficial effects on bone remodeling. Two monthly infusions led to increased osteoprotegerin (OPG) to RANKL (receptor activator of nuclear factor κB ligand) ratios, decreased Dickkopf-1 levels and increased sclerostin levels. OPG:RANKL increases were larger in the patients who achieved remission compared with those who did not.